Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election.
Afshar was promoted last year to oversee sales and manufacturing operations in North America and Europe. He previously worked in the office of the CEO.
During the study, 48 people living with hemophilia were treated with Hympavzi and observed to have a 93% reduction in annualized bleeding rate in 12 months.
Over the past six months, Pfizer’s shares (currently trading at $24.29) have posted a disappointing 8.5% loss while the S&P 500 was flat. This may have investors wondering how to approach the situation.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Pfizer’s first quarter results drew a positive market response as management emphasized margin improvement and disciplined expense control, even as revenue declined. CEO Albert Bourla credited robust execution in key therapeutic areas, particularly oncology and internal medicine, for helping offset lower sales from COVID-related products. CFO Dave Denton highlighted the impact of productivity programs and a refined commercial approach, noting that adjusted operating expenses fell meaningfully due to ongoing cost realignment. Management acknowledged external pressures, including U.S. policy changes and lower COVID demand, but pointed to operational efficiency as a key factor supporting profitability.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Looking for the most active stocks in the S&P500 index on Wednesday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest trading volume and driving market activity.
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such as Ireland and Bermuda, according to CNBC.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
